6月23日早间和誉在港交所公告公司之附属公司上海和誉生物医药科技有限公司(和誉医药)宣布一项在软骨发育不全(ACH)儿童

智通财经
23 Jun
6月23日早间和誉在港交所公告公司之附属公司上海和誉生物医药科技有限公司(和誉医药)宣布一项在软骨发育不全(ACH)儿童中开展的观察性研究完成首例患者入组。这项研究将为高选择性小分子FGFR2/3抑制剂ABSK061治疗ACH的研究收集患者的基线信息。今年3月ABSK061获中国国家药品监督管理局药品审评中心批准IND申请。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10